Integrated Medical Knowledge and
Range Safety Information
Q1. What is the gold standard for the suspected diagnosis of Celiac Disease?
Answer: Endoscopy with small intestine biopsy
Rationale: Endoscopy with small intestine biopsy is the gold standard for diagnosing Celiac
Disease. It allows for visualization of the small intestine and biopsy of tissue to detect the
characteristic damage caused by gluten intolerance.
Q2. What type of genetic mutation does this patient have, given that osimertinib (Tagrisso)
was started?
Answer: EGFR mutation
Rationale: Osimertinib (Tagrisso) is a targeted therapy for non-small-cell lung cancer that
specifically targets and inhibits the EGFR (epidermal growth factor receptor) mutation. This
mutation is often found in patients with advanced lung cancer.
Q3. Which condition is likely causing these symptoms in the 20-year-old male?
Answer: Becker muscular dystrophy
Rationale: Becker muscular dystrophy (BMD) is a genetic disorder that causes progressive
muscle weakness, often starting in the lower limbs. The patient's symptoms, including
difficulty with movement, falls, and muscle stiffness, align with BMD.
Q4. What should the provider say about the pathophysiology of SLE and its relation to
thrombocytopenia?
Answer: SLE disrupts immune homeostasis and promotes development of self-reactive
antibodies.
Rationale: Systemic lupus erythematosus (SLE) is an autoimmune disease that disrupts
immune homeostasis and leads to the development of self-reactive antibodies. These
antibodies can attack various tissues, including platelets, causing thrombocytopenia.
Range Safety Information
Q1. What is the gold standard for the suspected diagnosis of Celiac Disease?
Answer: Endoscopy with small intestine biopsy
Rationale: Endoscopy with small intestine biopsy is the gold standard for diagnosing Celiac
Disease. It allows for visualization of the small intestine and biopsy of tissue to detect the
characteristic damage caused by gluten intolerance.
Q2. What type of genetic mutation does this patient have, given that osimertinib (Tagrisso)
was started?
Answer: EGFR mutation
Rationale: Osimertinib (Tagrisso) is a targeted therapy for non-small-cell lung cancer that
specifically targets and inhibits the EGFR (epidermal growth factor receptor) mutation. This
mutation is often found in patients with advanced lung cancer.
Q3. Which condition is likely causing these symptoms in the 20-year-old male?
Answer: Becker muscular dystrophy
Rationale: Becker muscular dystrophy (BMD) is a genetic disorder that causes progressive
muscle weakness, often starting in the lower limbs. The patient's symptoms, including
difficulty with movement, falls, and muscle stiffness, align with BMD.
Q4. What should the provider say about the pathophysiology of SLE and its relation to
thrombocytopenia?
Answer: SLE disrupts immune homeostasis and promotes development of self-reactive
antibodies.
Rationale: Systemic lupus erythematosus (SLE) is an autoimmune disease that disrupts
immune homeostasis and leads to the development of self-reactive antibodies. These
antibodies can attack various tissues, including platelets, causing thrombocytopenia.
